Conflict of interest: none declared.
Clinical dermatology • Original article
Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS)
Version of Record online: 10 JUN 2011
© The Author(s). CED © 2011 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 36, Issue 7, pages 715–723, October 2011
How to Cite
Janmohamed, S. R., de Waard-van der Spek, F. B., Madern, G. C., de Laat, P. C. J., Hop, W. C. J. and Oranje, A. P. (2011), Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clinical and Experimental Dermatology, 36: 715–723. doi: 10.1111/j.1365-2230.2011.04080.x
- Issue online: 20 SEP 2011
- Version of Record online: 10 JUN 2011
- Accepted for publication 23 January 2011
Background. Haemangioma of infancy (HOI) is the most frequently occurring benign tumour of infancy. A good, reliable and objective scoring system for haemangioma activity is not yet available.
Aim. We have developed a simple system called the Haemangioma Activity Score (HAS) for scoring the (disease) proliferative activity of haemangiomas. The current study was undertaken to validate this system.
Methods. We validated the HAS in a comparative study of photographs taken during consultations from 2000 until 2008 (n = 78). Agreement between three observers was assessed at two different time points (t0 and t1) with a minimum interval of 6 months between them, using interclass correlation coefficients (ICC).
Results. Agreement between observers was good. The average ICC of the HAS at t0 and t1 was 0.72 and 0.76, respectively. The average ICC of the HAS for the changes from baseline (HAS at t0 minus HAS at t1) was 0.69.
Conclusions. We conclude that the HAS is a good system for scoring the proliferative activity of haemangiomas, and believe it to be useful in future investigations. The number of studies comparing different therapies for treating haemangiomas is steadily increasing, and the HAS (before and after treatment) may provide a valuable scoring system for evaluating such therapies.